Evolution of the Average Target: Eli Lilly and Company

Evolution of the Target Price: Eli Lilly and Company

Changes in Analyst Recommendations: Eli Lilly and Company

0d480c957fa38ca422bb4d21c72f.280plIdn9PiTIYp4lXm2LpL9QiIQzu7jAZ8bMXcJitE.qYFgpbQLho3kE9JB0x_-bKS1BkVkn7-Ic8lSHBFd2LuM-UPx_y3AzKtJww~42cd8c60da6b547da5baca7e121befc4
06-11 Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug FW
06-09 Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating MT
06-08 Sartorius Kept at Sell as Mwb Notes 'More Visible' Pharma Capex Risk MT
06-07 Eli Lilly and Company Announces Results Demonstrating Significant Weight Loss with Foundayo At Every Stage of Menopause CI
05-26 Analyst recommendations: Eli Lilly, AutoZone, BP plc, Ferrari, Samsung Electronics… Zonebourse
05-26 BofA Securities Raises Eli Lilly Price Target to $1,251 From $1,133 MT
05-22 Goldman Sachs reiterates Buy rating on Eli Lilly Zonebourse
05-21 Jefferies Lifts Eli Lilly Price Target to $1,330 From $1,300 MT
05-21 Bernstein Updates Novo Nordisk Price Target, Estimates After Wegovy Pill Launch Outperforms MT
05-18 Novo Nordisk slides on signs of slowing sales momentum for Wegovy pill FW
05-13 Analyst recommendations: Nvidia, Microsoft, Boeing, Eli Lilly, Siemens… Zonebourse
05-07 Rothschild & Co Redburn Adjusts Price Target on Eli Lilly to $900 From $880 MT
05-04 Barclays Adjusts Eli Lilly Price Target to $1,400 From $1,350, Maintains Overweight Rating MT
05-01 Eli Lilly Strong Q1 Results Show Stable Pricing, Foundayo Volatility Remains, RBC Says MT
05-01 Eli Lilly's Oral Weight-Loss Drug Gains Early Momentum as Prescriptions Surge, BofA Says MT
05-01 BofA Securities Cuts Eli Lilly Price Target to $1,133 From $1,294, Maintains Buy Rating MT
05-01 Morgan Stanley Adjusts Eli Lilly Price Target to $1,344 From $1,327, Maintains Overweight Rating MT
05-01 Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,119 From $1,058, Maintains Outperform Rating MT
05-01 Goldman Sachs Adjusts PT on Eli Lilly and Co. to $1,283 From $1,260, Maintains Buy Rating MT
05-01 Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $1,230 From $1,205, Maintains Overweight Rating MT
05-01 Truist Securities: Eli Lilly's Incretin Portfolio Bolsters Multi-year Growth Potential; Estimates Updated MT
05-01 BMO Adjusts Model for Eli Lilly After 'Standout' Q1 MT
05-01 RBC Ups Estimates for Eli Lilly Post-Q1 Results; Outperform Rating Kept MT
04-27 Global markets live: Eli Lilly, Meta Platforms, Microsoft, GSK… Zonebourse
04-27 Leerink Partners Adjusts PT on Eli Lilly and Co. to $1,058 From $1,296, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+7.31%
+4.98%
+11.34%
+9.32%
+0.97%
+22.3%
+8.54%
-0.76%
+25.46%
+11.36%
Average +10.08%
Weighted average by Cap. +8.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,133.00USD
Average target price
1,215.79USD
Spread / Average Target
+7.31%
High Price Target
1,500.00USD
Spread / Highest target
+32.39%
Low Price Target
850.00USD
Spread / Lowest Target
-24.98%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Jefferies & Co.
BofA Securities
Rothschild & Co Redburn
Barclays
Morgan Stanley
Leerink Partners
Goldman Sachs
Cantor Fitzgerald
Guggenheim
HSBC
Wolfe Research
RBC Capital Markets
Berenberg Bank
Daiwa Securities
CICC Research
Deutsche Bank Securities
Argus
Scotiabank
Truist Securities
BMO Capital
JPMorgan Chase
Wells Fargo Securities
TD Cowen
UBS
Bernstein
Citigroup
China Merchants
DBS Bank
First Shanghai
Redburn Atlantic
JEFFERIES Akash Tewari
China International Capital
DZ Bank
Morningstar
Credit Suisse
SVB Securities LLC
Cowen
Mizuho Securities
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,133.00USD
Average target price
1,215.79USD
Spread / Average Target
+7.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LLY Stock
  4. Consensus Eli Lilly and Company
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!